EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer: A Cohort Study

Carmine Valenza iD, Yue Zheng iD, Monica Milano, Dario Trapani iD, Elisa Giordano, Lorenzo Guidi, Pier Paolo Maria Berton Giachetti iD, Laura Boldrini, Grazia Castellano iD, Jalissa Katrini iD, Bianca Malagutti, Gabriele Antonarelli iD und 11 weitere

Journal of Clinical Oncology · 20.02.2026 · 44 (6) · 486-496

DOI: 10.1200/jco-25-01660 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.02.2026. Verfasst von Carmine Valenza und 22 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Chan School of Public Health, Harvard University, Boston, MA. Hauptthemen laut MEDLINE: Breast Neoplasms, Gonadotropin-Releasing Hormone, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To evaluate the clinical benefit of extended endocrine therapy (eET) after 5 years of adjuvant treatment with luteinizing hormone-releasing hormone agonists (LHRHa) in premenopausal women with node-positive, hormone receptor–positive early breast cancer (eBC). METHODS We conducted a cohort study analysis on two prospectively collected data sets (the Young Women's Breast Cancer Study and IEO Breast Cancer Cohort). Eligible patients were diagnosed with eBC at age ≤40 years (between 2005 and 2016), had node-positive, hormone receptor–positive disease, and remained premenopausal after 5 years of adjuvant LHRHa with no evidence of recurrence. The primary end point was invasive breast cancer–free survival (IBCFS), calculated from the sixth year after the initiation of adjuvant endocrine therapy (ET; study baseline), and adjusted through the propensity score (PS) weighting analysis. RESULTS A total of 501 patients were included in the analysis: 287 received eET for a median duration of 3.7 years (IQR, 2.3-5.0), including 48% tamoxifen monotherapy and 52% LHRHa plus tamoxifen or aromatase inhibitor. After a median follow-up of 7.3 years from the study baseline, the PS weighted IBCFS rates at 5 years were 85% in the eET group and 78% in the non-eET group (hazard ratio [HR], 0.63 [95% CI, 0.44 to 0.89]; P = .0135). The PS weighted distant recurrence-free survival rates at 5 years were 91% and 83% in the eET and non-eET group, respectively (cause-specific HR, 0.49 [95% CI, 0.31 to 0.79]). In both groups, bone fractures and major cardiovascular events were reported in 1% of patients. CONCLUSION In this cohort study analysis, extending ET in premenopausal patients with node-positive eBC after 5 years of LHRHa treatment was associated with a clinically meaningful reduction in both invasive and distant breast cancer recurrences.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsGonadotropin-Releasing HormoneAntineoplastic Agents, HormonalHumansFemalePremenopauseAdultChemotherapy, AdjuvantCohort StudiesReceptors, EstrogenTamoxifenProspective StudiesMiddle AgedReceptors, ProgesteroneDisease-Free SurvivalLymphatic MetastasisAromatase Inhibitors

Substanzen

Gonadotropin-Releasing HormoneAntineoplastic Agents, HormonalReceptors, EstrogenTamoxifenReceptors, ProgesteroneAromatase Inhibitors

Autor:innen und Institutionen

  • Harvard Chan School of Public Health, Harvard University, Boston, MA.
  • Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.
  • Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.
  • Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.

ORCID-Profile: Carmine Valenza, Yue Zheng, Dario Trapani, Pier Paolo Maria Berton Giachetti, Grazia Castellano, Jalissa Katrini, Gabriele Antonarelli, Fabio Conforti, Vincenzo Bagnardi, Gregory J Kirkner, Kate E Dibble, Marco Colleoni, Meredith M Regan, Elisabetta Munzone, Giuseppe Curigliano, Ann H Partridge

Zitieren

APA

Valenza, C., Zheng, Y., Milano, M., Trapani, D., Giordano, E., Guidi, L., Berton Giachetti, P. P. M., Boldrini, L., Castellano, G., Katrini, J., Malagutti, B., Antonarelli, G., Conforti, F., Pagan, E., Bagnardi, V., Kirkner, G. J., Sangalli, C., Dibble, K. E., Colleoni, M., …, & Partridge, A. H. (2026). Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer: A Cohort Study. Journal of Clinical Oncology, 44(6), 486-496. https://doi.org/10.1200/jco-25-01660

Vancouver

Valenza C, Zheng Y, Milano M, Trapani D, Giordano E, Guidi L, et al. Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer: A Cohort Study. Journal of Clinical Oncology. 2026;44(6):486-496. doi:10.1200/jco-25-01660

BibTeX
@article{Valenza2026,
  author = {Valenza, Carmine and Zheng, Yue and Milano, Monica and Trapani, Dario and Giordano, Elisa and Guidi, Lorenzo and Berton Giachetti, Pier Paolo Maria and Boldrini, Laura and Castellano, Grazia and Katrini, Jalissa and Malagutti, Bianca and Antonarelli, Gabriele and Conforti, Fabio and Pagan, Eleonora and Bagnardi, Vincenzo and Kirkner, Gregory J and Sangalli, Claudia and Dibble, Kate E and Colleoni, Marco and Regan, Meredith M and Munzone, Elisabetta and Curigliano, Giuseppe and Partridge, Ann H},
  title = {Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer: A Cohort Study},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {6},
  pages = {486--496},
  doi = {10.1200/jco-25-01660}
}
Kostenlos starten →